Benchmark Co. analyst Josh Sullivan reiterated a Buy rating on Ultralife (ULBI – Research Report) yesterday and set a price target of $14.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Josh Sullivan has given his Buy rating due to a combination of factors that highlight Ultralife’s promising growth trajectory. The recent acquisition of Electrochem has already exceeded expectations in terms of revenue and EBITDA, and its full integration is anticipated to be completed soon, further enhancing Ultralife’s market expansion into areas like pipeline inspection and seismic telemetry. Additionally, Ultralife is actively working on improving its gross margins through strategic pricing, cost management, and productivity enhancements, including the consolidation of facilities.
Furthermore, Ultralife’s focus on innovative product lines such as the Thin-cell medical wearables and ruggedized server cases presents significant growth opportunities. The FDA approval received by their partner for the medical wearable product is expected to lead to substantial orders, while advancements in battery technology and new product introductions in the communications sector are poised to drive future sales. These strategic initiatives, coupled with strong financial performance in the first quarter, underpin Sullivan’s optimistic outlook for the company’s stock.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ULBI in relation to earlier this year.